StreetInsider.com News Articles

Arvinas shares Phase 1 ARV-102 data for Parkinson's disease

Wed, 07 Oct 2026 07:00:13 -0400

Arvinas, Inc. (Nasdaq: ARVN) presented data from a Phase 1 clinical trial of ARV-102, an investigational oral PROTAC degrader targeting the LRRK2 protein, at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul, Korea.

The trial enrolled 24 patients with Parkinson's disease who received oral doses of ARV-102 ranging from 20 mg to 80 mg, or placebo, over 28 days. Key findings included dose-dependent improvements in saccadic hypometria, an objective measure of impaired eye movement associated with Parkinson's disease, compared with placebo.

The data also showed decreases in cerebrospinal fluid (CSF) biomarkers linked to endolysosomal function and neuroinflammation, increases

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Wed, 07 Oct 2026 07:00:00 -0400

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –

– Findings support continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation –

NEW HAVEN, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today presented novel data from a Phase

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Wed, 07 Oct 2026 07:00:00 -0400

– Findings support continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation –

Arvinas to present ARV-102 Parkinson's trial data at MDS congress

Thu, 01 Oct 2026 16:01:16 -0400

Arvinas, Inc. (Nasdaq: ARVN) said it will present biomarker data from a Phase 1 clinical trial of its investigational drug ARV-102 at the 2026 International Congress of Parkinson's Disease and Movement Disorders, scheduled for October 4-8, 2026, in Seoul, Korea.

The data will be featured in both a late-breaking oral presentation and an e-poster session on October 7. The oral presentation, titled "Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson's Disease: Oculomotor and Biomarker Data," is scheduled during Session 12 from 12:30 to 13:30 ET.

ARV-102 is an orally administered investigational compound designed to cross the blood-brain barrier and

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Thu, 01 Oct 2026 16:01:00 -0400

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea.

ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Thu, 01 Oct 2026 16:01:00 -0400

ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:01:00 -0400

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

The option

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:01:00 -0400

The option

Form S-8 ARVINAS, INC.

Mon, 28 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260928/27114416.html

Arvinas doses first patient in ARV-6723 Phase 1/2 trial

Mon, 28 Sep 2026 07:00:14 -0400

Arvinas, Inc. (Nasdaq: ARVN) announced that the first participant has been dosed in a Phase 1/2 clinical trial of ARV-6723, an investigational oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in adults with advanced solid tumors, according to a press release dated Sept. 28, 2026.

ARV-6723 is Arvinas' first clinical candidate in immuno-oncology and is described by the company as the first HPK1 PROTAC degrader to enter the clinic in the United States. HPK1 is a negative regulator of immune activation expressed across multiple immune cell types, including T cells, B cells, natural killer cells, and dendritic cells.

The ARV-6723-101

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Mon, 28 Sep 2026 07:00:00 -0400

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Mon, 28 Sep 2026 07:00:00 -0400

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

Form 144 ARVINAS, INC. Filed by: AGARWAL SUNIL

Tue, 22 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260922/27091478.html

Arvinas to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:01:00 -0400

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here.
Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. ET; webcast available here.
Morgan Stanley Annual Global Healthcare Conference on Wednesday,

Arvinas to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:01:00 -0400

Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here.
Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. ET; webcast available here.
Morgan Stanley Annual Global Healthcare Conference on Wednesday,

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:01:00 -0400

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

The RSU Award will vest in full on the one-year anniversary of the date of grant.

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:01:00 -0400

The RSU Award will vest in full on the one-year anniversary of the date of grant.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'